Cue Biopharma (CUE) Interest Coverage Ratio (2017 - 2025)
Cue Biopharma (CUE) posted Interest Coverage Ratio of 123.62 for Q4 2025, up 1053.84% sequentially from 12.96 in Q3 2025, and up 473.66% YoY from 21.55 in Q4 2024.
Cue Biopharma (CUE) Interest Coverage Ratio (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Interest Coverage Ratio for 9 years, with the latest figure at 123.62 in Q4 2025.
- Quarterly Interest Coverage Ratio rose 473.66% year-over-year to 123.62 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 68.08 (down 87.53% YoY) and the FY2025 annual result came in at 26.87, down 209.15% from the prior year.
- Interest Coverage Ratio improved to 123.62 in Q4 2025 per CUE's latest filing, from 12.96 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 123.62 in Q4 2025 and troughed at 149.87 in Q1 2022.
- A 5-year average of 22.31 and a median of 10.45 in 2021 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2022 and 2025: Interest Coverage Ratio slumped 7458.34% in 2022, then jumped 473.66% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 10.13 in 2021, then tumbled by 579.36% to 68.82 in 2022, then soared by 130.09% to 20.71 in 2023, then gained by 4.07% to 21.55 in 2024, then surged by 473.66% to 123.62 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 123.62, 12.96, and 1.46 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 123.63 |
| Sep 30, 2025 | -12.96 |
| Jun 30, 2025 | -1.46 |
| Mar 31, 2025 | -3.15 |
| Dec 31, 2024 | 21.55 |
| Sep 30, 2024 | -10.78 |
| Jun 30, 2024 | -1.96 |
| Mar 31, 2024 | -2.06 |
| Dec 31, 2023 | 20.71 |
| Sep 30, 2023 | -16.11 |
| Jun 30, 2023 | -95.19 |
| Mar 31, 2023 | -40.55 |
| Dec 31, 2022 | -68.82 |
| Sep 30, 2022 | -88.96 |
| Jun 30, 2022 | -63.54 |
| Mar 31, 2022 | -149.87 |
| Sep 30, 2021 | -10.13 |
| Mar 31, 2021 | -1.98 |
| Sep 30, 2020 | -1.17 |
| Mar 31, 2020 | -11.07 |